Our technology circulates a patient’s blood outside their body, similar to a dialysis blood loop, in order to capture and remove specific disease-causing agents. Where traditional dialysis is non-specific and relies on molecular weight to remove individual blood components, MediSieve uses specially engineered, biocompatible magnetic particles coated with binding agents (such as antibodies) to target specific components, and magnetic forces to extract the particles and targets they are bound to. The whole process takes place outside the body, enabling the removal of practically any component from blood, effectively providing a platform technology that could be used to treat a huge range of blood-borne medical conditions.
Currently, almost all blood-borne diseases are treated with pharmaceuticals which kill or block specific targets. This approach frequently has downsides including side effects, drug resistance, non-specificity and the inability to treat certain patients. In some cases, the toxins left behind in the patient’s bloodstream can lead to organ failure and death. By removing targets from the blood, MediSieve’s approach could avoid many of the issues caused by traditional drug treatments and offer a new therapeutic approach for blood borne diseases.
MediSieve is developing two core products:
A fully sterilised clinical prototype of the filter is now complete with first in man trials scheduled for 2018.
MediSieve’s initial target markets are Sepsis, Leukaemia and Malaria which represent a total addressable market of over £2.5B . Current treatments for these conditions leave the by-products of cell/pathogen death in the bloodstream, creating side effects and reducing the efficacy of treatment. Direct removal of the causative agents offers a new treatment modality for these serious illnesses. Working with some of the world’s leading experts, we have already begun research and development into the filter and magnetic particles for these diseases, and in-vivo testing is already underway on the first versions. As Malaria infected cells are naturally magnetic, the malaria product will only require use of the magnetic filter and not any magnetic particles.
MediSieve in the news
Created on 6/15/2018 6:07:52 PM
Ground-breaking medical blood treatment passes £1.75 million in funding
Created on 6/4/2018 10:53:54 AM